ALK inhibitors
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ALK inhibitors, covering 2024-07-15 to 2024-07-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors